{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:09:13Z","timestamp":1789236553810,"version":"build-2803163510"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2022,11,22]]},"abstract":"<jats:p>During the past few years, several innovative treatments for noncommunicable chronic disease have become available, including SGLT2i (sodium-glucose cotransporter-2 inhibitors), GLP-1a (glucagon-like-peptide 1 agonists), ARNI (angiotensin receptor-neprilysin inhibitors), and finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist. Each of these medications improves clinically relevant outcomes when added to existing therapies, and the indications for their use are rapidly expanding. Because existing drug regimens are already complex and costly, ensuring that society derives the maximal benefit from these new agents represents a major challenge. This Primer discusses how society can meet this challenge, which we address in terms of 5 principles: maximizing benefit, minimizing harm, optimizing uptake, increasing value for money, and ensuring equitable access. The Primer is most relevant for stakeholders in high-income countries, but the principles are broadly applicable to stakeholders in other settings, including low- and middle-income countries. We have focused the discussion on SGLT-2i, but the 5 principles herein could be used with reference to ARNI, finerenone, or any other health product.<\/jats:p>","DOI":"10.1161\/circulationaha.122.059032","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T19:00:31Z","timestamp":1669057231000},"page":"1627-1635","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Increasing Societal Benefit From Cardiovascular Drugs"],"prefix":"10.1161","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-3187","authenticated-orcid":true,"given":"Marcello","family":"Tonelli","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Calgary, Canada (M.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Straus","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Canada (S.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31824-9"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0289"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008165.pub4"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.07.005"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01774-9"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2019.10.004"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2018.04.008"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-020-01128-8"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-018-0836-4"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.008381"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1815"},{"key":"e_1_3_3_14_2","unstructured":"The Cochrane Collaboration. PROGRESS-Plus. 2022. Accessed April 26 2022. https:\/\/methods.cochrane.org\/equity\/projects\/evidence-equity\/progress-plus"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107813"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.03.017"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02381-3"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.07.119"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1107"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-07196-4"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-015-0295-0"},{"key":"e_1_3_3_22_2","unstructured":"The Cochrane Collaboration. Cochrane Effective Practice and Organisation of Care: About Us. 2022. Accessed April 26 2022. https:\/\/epoc.cochrane.org\/about-us"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000409.pub2"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054659"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000125.pub5"},{"key":"e_1_3_3_26_2","unstructured":"Boehringer I Eli Lilly and Company. A 12 month site randomized trial in adults with type 2 diabetes mellitus and history of cardiovascular disease (COORDINATE). 2022. Accessed July 7 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03936660"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-11-201212040-00538"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001431.pub5"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001174.pub4"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008194.pub3"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012419.pub2"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19271"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6645a2"},{"key":"e_1_3_3_34_2","unstructured":"AstraZeneca. Chronic kidney disease. 2021. Accessed May 6 2022. https:\/\/www.astrazeneca.com\/our-therapy-areas\/cardiovascular-renal-and-metabolism\/chronic-kidney-disease.html"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020030277"},{"key":"e_1_3_3_36_2","unstructured":"Diabetes Canada. Prescription for cardiovascular protection with diabetes. 2018. Accessed May 11 2022. https:\/\/guidelines.diabetes.ca\/docs\/resources\/prescription-for-cardiovascular-protection-with-diabetes.pdf"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S010"},{"key":"e_1_3_3_38_2","unstructured":"NICE. Type 2 diabetes in adults: management. 2022. Accessed May 11 2022. https:\/\/www.nice.org.uk\/guidance\/NG28"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.4338"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14501"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14076"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1005274"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007017.pub2"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00218"},{"key":"e_1_3_3_45_2","unstructured":"World Health Organization. Equitable access to essential medicines: a framework for collective action. 2004. Accessed July 7 2022. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/68571\/WHO_EDM_2004.4.pdf;jsessionid=63A05E3B382B9E2458F88BC59A30EFF4?sequence=1"},{"key":"e_1_3_3_46_2","volume-title":"Equitable access to high-cost pharmaceuticals","author":"Babar Z","year":"2018","unstructured":"Babar, Z, eds. Equitable access to high-cost pharmaceuticals. Academic Press, 2018."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.04.120"},{"key":"e_1_3_3_48_2","unstructured":"NHS Digital. NICE technology appraisals in the NHS in England (Innovation Scorecard) to December 2020. 2021. Accessed August 8 2022. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/nice-technology-appraisals-in-the-nhs-in-england-innovation-scorecard"},{"key":"e_1_3_3_49_2","unstructured":"Institute for Clinical and Economic Review. Mavacamten for hypertrophic cardiomyopathy: response to public comments on draft evidence report. 2021. Accessed August 8 2022. https:\/\/icer.org\/wp-content\/uploads\/2021\/10\/ICER_HCM_Public-Comment-Grid_100721.pdf"},{"key":"e_1_3_3_50_2","unstructured":"Institute for Clinical and Economic Review. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value. 2021. Accessed August 8 2022. https:\/\/icer.org\/wp-content\/uploads\/2021\/04\/ICER_HCM_Draft_Evidence_Report_81821.pdf"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.122.059032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T13:03:42Z","timestamp":1749042222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.122.059032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":49,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022,11,22]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.122.059032"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.122.059032","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"2022-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}